52 results about "Human placenta" patented technology

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The invention provides human placenta-derived vasogenic stem cells (hPASCs) and application thereof. The human placenta-derived angiogenic stem cells (hPASCs) disclosed by the invention are preserved in China Center for Type Culture Collection, Wuhan University, Wuhan, China; the preservation date is April 2, 2025; the preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The hPASCs disclosed by the invention contain angiogenic cell subgroups, have stem cell stemness, have an angiogenesis effect in vivo and in vitro, and can be used for treatment of diseases such as cardiovascular diseases and vascularization construction of artificial organs and tissues.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.

The present disclosure provides compositions and methods related to the culturing of trophoblast stem cells (TSCs). In particular, the present disclosure provides novel formulations and methods for inducing and maintaining trophoblast stem cells obtained from cytotrophoblasts (CTBs) obtained from a placenta at birth. The compositions and methods described herein allow for the development of in vitro models of early human placental development and establish a platform for therapeutic discoveries.

One or more techniques and / or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin.

The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of radix salviae miltiorrhizae, 8 to 15 parts of rhizoma chuanxiong, 12 to 20 parts of radix angelicae sinensis, 7 to 15 parts of herba lycopi, 15 to 30 parts of poria cocos, 8 to 15 parts of human placenta, 18 to 30 parts of herba speranskiae tuberculatae, 15 to 25 parts of caulis spatholobi, 25 to 40 parts of radix paeoniae alba, 12 to 20 parts of radix rehmanniae and 8 to 15 parts of liquorice root. The traditional Chinese medicine composition takes salvia miltiorrhiza, ligusticum wallichii, angelica sinensis, herba lycopi, poria cocos, human placenta, garden balsam stem, caulis spatholobi, radix paeoniae alba, radix rehmanniae and liquorice as raw materials, follows the medication principle of monarch, minister, assistant and guide of traditional Chinese medicines, can tonify the liver and kidney and promote blood circulation to remove blood stasis by combining the medicines, and has a good treatment effect on liver and kidney deficiency and qi stagnation and blood stasis type knee arthralgia.

The invention discloses a traditional Chinese medicine composition for treating sepsis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from 1-15 parts of sulfur, 3-25 parts of calamitas urinae hominis, 1-20 parts of wine-treated rhubarb, 10-30 parts of fructus cannabis, 10-50 parts of radix bupleuri, 5-30 parts of scutellaria baicalensis, 5-25 parts of folium isatidis, 5-25 parts of peach kernels, 5-30 parts of salvia miltiorrhiza, 5-30 parts of angelica sinensis, 5-30 parts of sophora flower charcoal, 5-25 parts of fructus gardeniae praeparatus and 5-60 parts of wine-treated fructus corni. According to the invention, through a combined mode of'monarch drug targeted oral administration and synergistic decoction of minister, assistant and guide drugs', the whole-course intervention of'upstream inhibition, midstream blocking and downstream regulation 'on sepsis immune disorder can be realized, meanwhile, the functions of warming yang, dispelling cold, cooling blood and detoxifying are taken into account, and the pro-inflammatory / anti-inflammatory balance is successfully recovered to a physiological state; the action mode is superior to that of a traditional single anti-inflammatory strategy and a traditional Chinese medicine application mode of whole-prescription decoction. In a standard animal model, the traditional Chinese medicine composition definitely shows the dose-dependent extremely remarkable effects of anti-inflammation, immunoregulation, multi-organ protection and overall condition improvement, the curative effect of a high-dose group of the traditional Chinese medicine composition is equivalent to that of a classic potent medicine, and the traditional Chinese medicine composition has more advantages in the aspects of recovering immune homeostasis, warming yang and strengthening the body resistance.

The invention relates to a nasal administration preparation containing extracellular vesicles and acellular matrix hydrogel and a preparation method of the nasal administration preparation, and belongs to the technical field of extracellular vesicles. According to the nasal administration preparation, the nasal administration preparation contains extracellular vesicles, acellular matrix hydrogel and auxiliary materials, and the auxiliary materials contain at least one of a lipophilic solvent, a humectant, a thickening agent and an osmotic pressure regulator. The EVs nasal administration dosage form is prepared, the EVs has the capacity of passing through a blood brain barrier, can be delivered to a brain central nervous system and has high brain administration capacity, the human placenta source ECM forms nanofibers through structural regulation and control, the nanofibers are used as a carrier material of the EVs, long-term storage of the biological activity of the EVs can be achieved, the local treatment time of the EVs is prolonged, and the EVs nasal administration dosage form can be applied to the brain. EVs can be efficiently absorbed in the nasal cavity, and compared with similar products, the effective component acting time is longer.

Provided according to one aspect of the present disclosure is a composition for wound healing or tissue regeneration that comprises a genomic DNA fragment extracted from human placenta-derived mesenchymal stem cells and a placental growth factor and which exhibits excellent tissue regeneration ability. Provided according to another aspect of the present disclosure is a preparation method which enables the efficient, biocompatible, economical, and environmentally friendly production of a composition for wound healing or tissue regeneration having excellent tissue regeneration ability.

The invention relates to construction of a proline hydroxylase alpha subunit mutant from a human placenta and an expression vector of the proline hydroxylase alpha subunit mutant, and a mutant protein which is efficiently expressed in Ecoli BL21 (DE3) and has greatly improved hydroxylation efficiency and a construction body of the mutant protein are obtained by analyzing and screening a natural hydroxylase subunit.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present invention relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell microtissue model, while simultaneously allowing for the application of mechanical stimuli such as luminal flow and / or lateral flow. Embodiments include three cultures representing the maternal-fetal interface (placental barrier): human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human placental pericytes (HPP), as well as a ductal interface composed of human primary mammary gland-derived endothelial cells, fibroblasts, and epithelial layer (MCF10). The model is expandable to include tumors (cell line-derived or patient-derived). The present invention further relates to a method for fabricating a human 3D vascular microtissue model using a microfluidic device according to the present invention, and to the use of a human 3D vascular microtissue model for, for example, studying the effects of cell barrier function (solute permeability), interstitial flow, luminal flow and / or lateral flow, and epithelial and / or endothelial barrier function (solute permeability), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present invention further relates to a method for presenting a pre-eclampsia (disease) model of the placental barrier, and means for testing drug therapies.

The invention relates to the technical field of cell extraction, in particular to a preparation method of a whole tissue single-cell suspension of human placenta villus tissue. The preparation method of the human placenta villus tissue single-cell suspension has the advantages of being small in digestive enzyme dosage, short in digestion time and high in cell activity, the prepared single-cell suspension is high in total cell concentration, the cell activity is 90% or above, the caking rate is low, the placenta villus tissue whole-tissue single-cell suspension can be rapidly prepared in a large scale, operation is easy, and the preparation method is suitable for industrial production. The method is simple in operation and low in reagent cost, can effectively retain the activity of whole tissue cells and the integrity of cell membranes, overcomes the defects of complicated operation, low cell activity and the like in the existing method, and has better application value in the fields of placenta villus tissue cell culture, organoid culture, flow cytometry, single cell sequencing and the like.

The invention discloses a human endothelial progenitor cell culture medium and application thereof in preparation of extracellular vesicles. The formula of the human endothelial progenitor cell culture medium is as follows: human platelet lysate with the volume concentration of 3-10%, VEGF (vascular endothelial growth factor) with the volume concentration of 60-200ng / mL, IGF (insulin-like growth factor) with the volume concentration of 20-100ng / mL, L-glutamine with the volume concentration of 2-10mM, sodium pyruvate with the volume concentration of 0.02-0.75 mM, glucocorticoid with the volume concentration of 50-250ng / mL and a reducing agent with the volume concentration of 50-200mu M are added into a basic cell culture medium; the human endothelial progenitor cells are human placenta tissue-derived endothelial progenitor cells. Animal-derived reagents are not involved, the price is low, the number of EPCs extracellular vesicles obtained through amplification is large, the purity is high, and the skin wound repairing effect is good. The extracellular vesicles are easy to produce on a large scale, convenient to store and control batch quality, simple to obtain and use and free of immunological rejection.

The invention relates to the technical field of immune cells, in particular to a preparation method of human placenta-derived NK cells. The preparation method comprises the following steps: S1, separating placenta tissues; s2, placenta tissue digestion; S3, mononuclear cell separation; S4, NK cell sorting; and 5, NK cell multiplication culture.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The invention relates to the technical field of somatic cell reprogramming and cell transplantation therapy, in particular to a chemical induction method for reprogramming human placenta fibroblasts into pluripotent stem cells, which comprises the following steps: taking in-vitro human placenta fibroblasts, and reprogramming the in-vitro human placenta fibroblasts into induced epithelial-like cells under the action of TTNPB, calorphin, RepSox, Tranylcyromine and valproic acid; according to the method, the induced epithelial cells are subjected to continuous induction by utilizing a piripotent element, RepSox, TTNPB, Tranylcyromine, valproic acid, EPZ004777, AM580, CHIR99021 and DZNep, and finally, the induced pluripotent stem cells are obtained. According to the method, the reprogramming process only comprises two specific stages, the induction duration is greatly shortened, and the reprogramming cell induction efficiency is 0.0678% + / -0.0055%-0.0719% + / -0.0185%.

The invention discloses a human placenta organoid gene intervention method based on lentivirus transfection, and belongs to the technical field of biological medicine. According to the method, key parameters of lentivirus transfection, namely the volume ratio of cell suspension to lentivirus to DMEM (Dulbecco Modified Eagle Medium) of 10: 2: 40 and the optimal transfection time of 4 hours, are optimized and determined, so that high transfection efficiency is ensured, the adverse effect of the virus on the activity of the organoid is remarkably reduced, and good organoid balling capacity and normal growth state are maintained. According to the invention, stable and controllable gene intervention is realized in a three-dimensional organoid model which highly simulates the structure and function of a human placenta for the first time, and the obtained placenta organoid subjected to gene intervention has a great significance for deeply researching the molecular mechanism of placenta development in a highly bionic in-vitro environment and exploring the pathogenesis of pregnancy-related diseases such as preeclampsia and the like. And an ideal research platform which is reliable and close to the physiological state is provided by screening or evaluating intrauterine gene therapy strategies.

The invention belongs to the technical field of biology, and particularly relates to separation and application of proteasome-rich human placenta-derived vascular stem cell outer vesicles. The extracellular vesicles provided by the invention are derived from human placenta source blood vessel promoting stem cells, and the human placenta source blood vessel promoting stem cells show that markers PAI-1 are positive, MECOM is positive, CD201 is positive, CD44 is positive, CD73 is positive, HLA-ABC is positive, CD34 is negative, CD31 is negative and CD326 is negative. Compared with human umbilical cord mesenchymal stem cell outer vesicles, the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes and angiogenic protein factors, wherein the proteasomes have high chymotrypsin-like activity. Moreover, in-vivo and in-vitro experimental data show that the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes, and can degrade accumulation of HIF and inhibit cell apoptosis; the medicine has a treatment effect on myocardial infarction.

The invention discloses a preparation method of traditional Chinese medicine composition gecko pills for treating lung diseases, and relates to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition gecko pills comprise 20 parts of abelmoschus manihot, 12 parts of gecko, 12 parts of human placenta, 12 parts of ginseng, 10 parts of fritillaria, 10 parts of almond, 10 parts of lily, 10 parts of rhizoma polygonati, 10 parts of medlar, 10 parts of cistanche, 10 parts of astragalus membranaceus, 10 parts of cynomorium songaricum, 10 parts of fried malt and 10 parts of endothelium corneum gigeriae galli. Abelmoschus manihot, fritillaria, almond, lily, polygonatum kingianum, medlar, cistanche, astragalus membranaceus, cynomorium songaricum, fried malt and endothelium corneum gigeriae galli are cleaned and then dried at the low temperature of 55 DEG C until the water content is lower than 7%. The gecko and the human placenta are used as monarch drugs to tonify the lung and the kidney, absorb qi and relieve asthma; the ginseng and the astragalus membranaceus tonify qi and strengthen superficies, and the fritillaria and the almonds reduce phlegm and The abelmoschus manihot, the rhizoma polygonati and the Chinese wolfberry have the effects of nourishing yin and moistening lung; roasted malt and endothelium corneum gigeriae galli are used for strengthening spleen and stomach, and preventing greasy Effective components with different polarities are fully extracted by a three-stage countercurrent extraction process; and the bioavailability of the animal medicinal materials is improved by a superfine grinding technology.

The invention relates to the technical field of traditional Chinese medicine preparation, in particular to a film-nourishing pregnancy-assisting bag and a preparation method thereof.The preparation method comprises the steps that 1, raw materials are prepared, specifically, traditional Chinese medicine clean material decoction pieces of mulberries, lycium ruthenicum, human placenta and dendrobium officinale are weighed; and the site cleaning work is completed after weighing. 2, crushing and sieving: mixing the weighed clean material decoction pieces, and carrying out coarse crushing; and performing fine crushing after coarse crushing. Step 3, drying and sterilizing: spreading the sieved medicinal powder in a tray filling device respectively; and drying and sterilizing. And step 4, mixing and sieving: mixing the sterilized medicinal powder again. 5, medicine split charging, wherein the medicine powder mixed again is split charged in a sterile workshop. And step 6, labeling and warehousing: after sub-packaging, carrying out label printing and outer packaging labeling. According to the invention, the safety of the product is ensured through efficient crushing and uniform mixing and by adopting a drying and sterilizing mode for treatment.

The invention discloses a traditional Chinese medicine preparation for treating anemia diseases. The traditional Chinese medicine preparation is prepared from codonopsis pilosula, angelica sinensis, astragalus membranaceus, human placenta, fructus psoraleae, caulis spatholobi, dogwood, prepared rehmannia root, herba epimedii, morinda officinalis, fructus lycii, radix paeoniae alba, ligusticum wallichii and donkey-hide gelatin. The traditional Chinese medicine composition adopts pure traditional Chinese medicine components, promotes and stimulates the bone marrow hematopoiesis function to achieve the purpose of treating anemia through the effects of invigorating spleen, replenishing qi, nourishing yin, enriching blood, tonifying kidney and replenishing marrow, is not limited to immediate relief of symptoms and short-term improvement of blood indexes, and focuses on fundamental recovery of bone marrow hematopoiesis and enhancement of body immunity; the traditional Chinese medicine composition has the advantages that the anemia problem is fundamentally solved, repeated attack of diseases is effectively restrained, and the traditional Chinese medicine composition has excellent wide applicability, has unique comprehensive effects of invigorating spleen and replenishing qi, nourishing yin and blood, and tonifying kidney and marrow, and can be accurately butted with anemia types under different pathological mechanisms, such as malnutrition anemia, tumor-related anemia and hemolytic anemia.

The invention relates to the technical field of biological medicine, in particular to an autophagosome for promoting hair growth and an extraction method and application thereof. Comprising the following steps: inoculating human umbilical vein endothelial cells or human placenta mesenchymal cells into a DMEM (Dulbecco Modified Eagle Medium) complete medium, and culturing until the cell fusion degree reaches 80-90%; replacing the DMEM complete culture medium with a serum-free DMEM culture medium, collecting supernate after culture is completed, and centrifuging the supernate to obtain a crude extract containing the autophagosome; and resuspending the crude extract by using PBS, adding an LC3 antibody, and finely extracting by using a paramagnetic particle method to obtain the autophagosome. The method has the advantages of simple operation process, no need of other inducers in the process of inducing the formation of the autophagosome, no too high requirements on laboratories, and high yield of the autophagosome, and provides an efficient, convenient, economical and practical treatment means for alopecia patients.

The invention relates to the technical field of stem cells, in particular to a preparation method of human placenta amnion pluripotent stem cells. The method specifically comprises the following steps: S1, tissue pretreatment and physical pre-layering; s2, carrying out mechanical-enzymatic synergistic dynamic dissociation; s3, gradient purification and washing; s4, performing soft matrix phenotype maintenance culture; according to the method disclosed by the invention, the separation efficiency of amniotic epithelial cells is improved and the enzyme exposure load is reduced through synergistic enzymolysis of Dispase II and Trypsin in combination with weak shearing force generated by the magnetic beads. Meanwhile, SB431542 blocks a signal channel to prevent EMT, a GelMA soft matrix maintains cell phenotypes, and Percoll density gradient centrifugation is matched to improve cell purity.

The utility model relates to the technical field of placenta extract purification, and discloses a human placenta extract purifying and filtering device which comprises a bottom cabinet, a material box, a limiting elastic assembly and a carrying disc seat, the material box is fixedly installed on the bottom cabinet through a support, a box cover is fixedly installed at the top of the material box, a top frame is fixedly installed at the upper end of the box cover, and a limiting elastic assembly is fixedly installed at the lower end of the top frame. The limiting elastic assembly is arranged between the top frame and the tray carrying seat, a miniature vibration motor is fixedly installed at the upper end of the tray carrying seat, a rotating motor is fixedly installed at the bottom end of the tray carrying seat, a vertical shaft is fixedly connected to the driving end of the rotating motor, and the vertical shaft penetrates through the box cover and extends into the material box. According to the utility model, the extract can be subjected to double-layer centrifugal filtration treatment, so that the extract can be quickly and thoroughly filtered, and the purification efficiency and effect of the extract can be ensured.

The invention provides a composition for treating male erectile dysfunction by combining human prepuce mesenchymal stem cell exosome with human placenta mesenchymal stem cells and application, and relates to the technical field of biological medicine. The composition comprises human prepuce mesenchymal stem cell exosome particles and human placenta mesenchymal stem cells. The human prepuce mesenchymal stem cell exosome particles and the human placenta mesenchymal stem cells are core components and have the repairing effects of revascularization, nerve repairing, fibrosis resistance and the like. The composition also comprises glutathione, L-arginine, icariin, ginseng stem and leaf total saponins, mecobalamin and human serum albumin, can provide functional support and antioxidant protection, ensures the instant effect, and creates an environment for restoration. According to the invention, multi-target and fundamental treatment of male erectile dysfunction is realized through an action mode of quick effect taking, synergistic repair and long-acting reconstruction, and symptoms of male erectile dysfunction are remarkably improved.

The invention belongs to the technical field of biomedicine, and relates to a culture medium for human placenta organoid in early pregnancy as well as preparation and application of the culture medium. The culture medium is prepared from DMEM / F12, and an N-2 additive is added into the culture medium; a B-27 additive; primary cell antibiotics; and N, N-acetyl-L-cysteine; l, L-glutamine; recombinant human epidermal growth factors; cHIR99021, CHIR99021; a recombinant human R-spinal protein 1; recombining a human fibroblast growth factor; recombinant human hepatocyte growth factors; a83-01, A83-01; prostaglandin E2; y-27632, Y-27632; and fetal bovine serum albumin. By improving the components of the culture medium of the human placenta organoid, the obtained human placenta organoid is better in growth state and balling rate, the apoptosis of the organoid is reduced, and a foundation is laid for further application to research of downstream molecular biology and cytobiology.

The invention discloses a stably produced mesenchymal stromal cell exosome containing anti-inflammatory miRNA effective components and a preparation method and application of the mesenchymal stromal cell exosome. The preparation method comprises the following steps: S1, obtaining placenta tissues, and performing isolated culture on primary placenta mesenchymal stromal cells; s2, constructing an immortalized placenta mesenchymal matrix cell line through a lentivirus transduction hTERT gene; s3, culturing the immortalized placenta mesenchymal matrix cell line in a serum-free culture medium, and collecting a cell supernatant; s4, the obtained supernate is sequentially subjected to centrifugation, PEG precipitation and ultrafiltration concentration, and exosome is extracted. According to the invention, hTERT immortalized human placenta mesenchymal stromal cells (iMSC022) of a single donor are adopted as a production source of the exosome (Exo), so that the application limitation of traditional primary cells is remarkably broken through. Compared with a mode that a primary mesenchymal stromal cell (MSC) needs to depend on multi-donor mixing to construct a cell bank due to limited multiplication capacity, the iMSC022 has high homogeneity after lentiviral transfection and resistance screening.

One or more techniques and / or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin.

Described herein relates to novel methods for determining susceptibility for infection and / or disease (e.g., pregnancy complication and / or cancer), and / or predicting severity of infection and / or disease by measuring circulating Alu RNA by RT-PCR (e.g., circulating blood, serum, and / or plasma). Additionally, described herein relates to novel methods of treating infection and / or disease (e.g., pregnancy complication and / or cancer), via increasing immune response, optimizing vaccine delivery, via administering at least one Alu RNA into the subject.